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Background: Cardiac gene therapy for heart disease is a major translational research area with potential, yet
problems with safe and efficient gene transfer into cardiac muscle remain unresolved. Existing methodology to
increase vector uptake include modifying the viral vector, non-viral particle encapsulation and or delivery with device
systems. These advanced methods have made improvements, however fail to address the key problem of inflammation
in the myocardium, which is known to reduce vector uptake and contribute to immunogenic adverse events. Here we
propose an alternative method to co-deliver anti-inflammatory drugs in a controlled release polymer with gene
product to improve therapeutic effects.
Methods: A robust, double emulsion production process was developed to encapsulate drugs into nanoparticles.
Briefly in this proof of concept study, aspirin and prednisolone anti-inflammatory drugs were encapsulated in various
poly-lactic glycolic acid polymer (PLGA) formulations. The resultant particle systems were characterized, co-delivered
with GFP plasmid, and evaluated in harvested myocytes in culture for uptake.
Results: High quality nanoparticles were harvested from multiple production runs, with an average 64 ± 10 mg yield.
Four distinct particle drug system combinations were characterized and evaluated in vitro: PLGA(50:50) Aspirin, PLGA
(65:35) Prednisolone, PLGA(65:35) Aspirin and PLGA(50:50) Prednisolone Particles consisted of spherical shape with a
narrow size distribution 265 ± 104 nm as found in scanning electron microscopy imaging. Prednisolone particles
regardless of PLGA type were found on average ≈ 100 nm smaller than the aspirin types. All four groups demonstrated
high zeta potential stability and re-constitution testing prior to in vitro. In vitro results demonstrated co uptake of GFP
plasmid (green) and drug loaded particles (red) in culture with no incidence of toxicity.
Conclusions: Nano formulated anti-inflammatories in combination with standalone gene product therapy may offer a
clinical solution to maximize cardiac gene therapy product effects while minimizing the risk of the host response in the
inflammatory myocardial environment.
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Acquired heart disease from myocardial infarction (i.e.
heart attack) remains the leading cause of mortality and
morbidity worldwide, with 22 million new patients diag-
nosed annually. Essentially, all approved pharmacologic
and device systems impose significant cost burden to the
health system, yet fail to increase survival rates [1-3].
Heart transplant, which is the gold standard for patients,
will never meet clinical demand due to the chronic short-
age of viable donors [4,5]. Therefore, new therapeutic
approaches to manage the disease burden represent a
significant unmet need. Recently, sophisticated molecular
profiling tools combined with a deeper knowledge base
derived from disease models have ushered in a new era of
biopharmaceutical development for heart disease. This
has resulted in the development of a more potent class of
therapies designed to act at the myocyte level, whereby
therapeutic action is achieved primarily through DNA,
RNA and or microRNA genetic reprogramming [6]. Vari-
ous gene therapy concepts have been applied successfully
in animal models demonstrating increased contractility,
repaired myocardium, and or regenerated new vessels to
reduce myocardial infarction reoccurrence [7-10]. Inde-
pendent of the targeted gene mechanism, the most
common means to achieve these aims are with either
bioengineered viral or non-viral vector biologics, since
the uptake and success rates of naked molecular ther-
apies is very poor in vivo [11,12]. The most effective
gene products today have shown remarkable promise,
but at the same time have also presented more risks
and complicated translational issues, especially when
compared with traditional pharmaceutical compounds.
Despite the availability of effective transgene-vector
systems, one major rate limiting problem is with achiev-
ing safe and efficient myocardial gene transfer in the
clinic [13,14]. Due to size scale and more complex mem-
brane barriers, these issues do not emerge in smaller
animal studies yet are a major challenge in larger organ-
isms [15,16]. Although the preferred route of adminis-
tration in clinical trials, it remains controversial whether
or not minimally invasive catheter infusion approaches
can yield sufficient therapeutic expression levels that sig-
nificantly improve outcomes in the clinic [17]. Another
major problem with these systems is restricting thera-
peutic expression to the heart and minimizing off target
effects. In fact, published large animal data has demon-
strated a greater than 2000 fold higher presence in
collateral organs versus the heart [18-20]. Alternatively,
direct myocardial delivery methods can restrict thera-
peutics to the heart if safely administered.
Direct myocardial delivery methods (e.g. needle injec-
tion, sonoporation) can offer greater cardiac specificity
of gene therapeutics compared to percutaneous infusion
approaches. The key unresolved problem is with thelimited distribution of gene therapeutic per delivery site
requiring many injections [21]. Increasing the number of
injections has the adverse effect of triggering inflamma-
tion in the myocardium, thus limiting the availability of
additional injection sites and jeopardizing the retained
therapy. The immune response to gene therapy prod-
ucts, especially notorious with the viral mediated products,
is complex but several key studies have demonstrated a
clearer relationship between inflammation and the in-
creased risk of an adaptive immune response [22,23].
Therefore it is postulated the use of an anti-inflammatory
drug co-delivered with the gene therapy product could:
(1) Address the inflammation to minimize the adaptive
immune response and promote therapeutic tolerance (2)
increase trafficking and uptake in a more favorable
microenvironment and (3) potentially permit more
injection sites.
This concept of a direct injection drug/gene approach
has yet to be translated into the heart, whereby problems
exist with increasing uptake and extending the half-life
of anti-inflammatory drugs at the site of injection be-
yond the peak acute inflammatory window of 48 hours.
In addition to the timing issue, the anti-inflammatory
load must not interfere with vector trafficking or the
subsequent gene expression efficiency. Numerous stud-
ies have explored of advanced non-viral vectors to in-
crease in vivo performance by means of transfection
alone [24,25]. However, none have attempted to use
anti-inflammatories at the injection site co-delivered
with a higher risk, but optimal gene transfer vector to
provide a more promising clinical strategy. This study
summarizes the development and parameter testing of a
reliable nanoscale anti-inflammatory formulation pro-
duction process for co-delivery with gene products. The
development phase features aspirin and prednisolone,
two widely utilized anti-inflammatories and incorporates
them into two common FDA approved poly lactic gly-
colic acid (PLGA) polymers [26]. Complete nanoparticle
characterization, process tolerance limits and an in vitro
feasibility assessment in harvested myocytes are offered to
evaluate the concept of a drug/gene combination therapy.
Methods
Poly-lactic glycolic acid nanoparticle production process
Pre-Processing Steps:
A water oil water (w/o/w) double emulsion process
outlined in (Figure 1) was executed to generate aspirin
(99% pure, Sigma Aldrich USA) and prednisolone (99%
pure, Sigma Aldrich USA) loaded poly- lactic glycolic acid
(PLGA) nanoparticles (NPs). First, initial drug load water
phase stocks of 1–3 mg/mL aspirin and 0.1-0.4 mg/mL
prednisolone were created by dissolving in 1% poly vinyl
alcohol (PVA) solution. In the case of prednisolone due to
Figure 1 The water oil water double emulsion nanoparticle production process work flow sequence to generate high quality
anti-inflammatory formulations.
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These doses were selected based on body weight and
pharmacokinetic data for the rodent species. The second
step or oil phase was generated in a separate vial, with
PLGA, input mass range (20–120 mg) of one of either
types (50:50, 65:35 i.e. % of lactic: glycolic acid chains)
dissolved in 2.5 mL of Dichloromethane. For the in vitro
study only, production runs were carried out as described
in the methods above except 100 μg of Rhodamin B dye
powder was added to the first drug water phase.
Process Steps:
The first emulsion was created by adding 1 mL of as-
pirin or prednisolone drug PVA 1% solution dropwise to
the oil phase polymer in a 5 mL glass vial under probe
sonication. After 3 minutes, this resultant emulsion was
then added dropwise to a larger outer water phase con-
taining 15 mL of PVA 1% to create the double emulsion.
The double emulsion was then placed in a fume hood
and stirred gently for at least 24 hours to facilitate
solvent evaporation and particle formation. Separation
was achieved with via ultra-centrifugation at 30,000 g for
35 min at 10C. The resultant particle pellets were washed
to remove residual drug/polymer, then freeze dried over-
night. Four nanoparticle compositions were generated
with the reaction: PLGA (50:50 Aspirin), PLGA (65:35
Aspirin), PLGA (50:50 Prednisolone) and PLGA (65:35
Prednisolone).
Post-Processing:
All yields were weighed then stored in sterile cryovial
containers at -20C.Scanning electron microscopy (SEM) analysis &
characterization
Approximately 5 mg of each freeze dried NP sample was
prepared for SEM with gold sputter coating, and then im-
aged on a JEOL SEM unit at 1.00 kV between 10–20,000 x.Multiple images were taken from separate locations on the
field with focus in the range of 1 um to 500 nm.
Stability testing
24 hour formulation stability test
Saline stability re-constituted particles tests were also
conducted. Ten mg of freeze dried nanoparticles were
dissolved and probe sonicated in sterile 0.9% saline water
and allowed to settle over a 24 hour period. Repeat
droplets were first dried and sputter coated for loading
into the SEM.
Zeta potential colloidal stability measurements
A sample of each particle composition was prepared in
water and added to testing cuvettes per manufacturer in-
structions of the Zetasizer Nano ZS instrument (Malvern
Instruments, UK). Triplicate runs were averaged to repre-
sent a single data point for multiple samples from the
same production lot.
Controlled release & loading efficiency analysis
A UV–vis spectrophotometer (NanoDrop, National In-
struments) was used to generate two separate standard
curves for serial dilutions of known drug concentrations.
The wavelength consistent with aspirin detection was
275 nm and 235 nm for prednisolone.
Drug loading efficiency calculations
To compute loading efficiency, the amount of either as-
pirin or prednisolone encapsulated in the nanoparticle
formulations was determined by measuring the residual
amount in the supernatant following centrifugation rela-
tive to the initial load in the water phase. Percentage
was derived as the mass amount of drug remaining in
the supernatant following separation.
Controlled release analysis
High quality yields were selected based on the most potent
drug formulation of 5 wt. % PLGA aspirin and 1.5% PLGA
prednisolone were manufactured per process specifications.
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lease studies as follows: (1) 20 mg of particle was dissolved
into 10 mL of 42C (2) Samples for spectrophotometry ana-
lysis were removed with a syringe 450 nm filter at 12 hours,
1, 2, 3, 4, 5 days (3) The sample volume was replaced and
the process repeated for each interval up until the final
point (4) Triplicate UV–vis spectrophotometry measure-
ments against the standard curve for each drug were per-
formed on each sample to determine the percentage
released for each run.
In vitro testing protocol
Neo-natal rat cardiac-myocyte harvesting
Day 0 to 3 neonatal pups are used and the pups were
euthanatized by decapitation and the heart was immedi-
ately removed with forceps. The atria and great vessels
were removed and the left ventricular tissue was minced
and subjected to a trypsin-based disaggregation proced-
ure in a 6 well plate with ethanol cleaned scissor, rinsed
with HBSS with 1% P/S/G, and place in a 50 ml conical
tube containing 10 ml of Trypsin solution for shaking
(200 rpm) at 37C for 15 min. Cells were then centri-
fuged at 660 rpm at 4c for 5 minutes. The supernatant
was discarded and the cells were re-suspended in 20 ml
of media and pre-plate for 1–3 hours in the incubator.
Harvested cells were collected with centrifuge spin at
660 rpm for 5 min at room temperature. Cell pellets for
experiments were then placed in the culture media and
counted using 0.4% Trypsin blue.
Plasmid GFP DNA & tagged nanoparticle preparation
A 10 mg master aliquot of eGFP plasmid DNA was ob-
tained from Invitrogen and handled according to manu-
facturer’s instructions. Under sterile conditions working
yields for each well were created with, 6 μg of DNA was
diluted into 100 μL of RNAase free water. Separately
10 mg of each of the process output 4 resultant particle
systems [PLGA50:50-Aspirin, PLGA50:50-Prednisolone,
PLGA65:35-Aspirin, PLGA65:35 Prednisolone] tagged with
Rhodamin B was finely crushed and mixed into 20 mL of
phosphate buffer saline. To remove residual dye not bound
within the particle structure, the particle solution was placed
into a dialysis membrane submerged in an outer bath of
PBS at 37. Prior to well transfection, 10 μg of each nanopar-
ticle solution in 500 μL was placed in individual aliquots.
DNA and nanoparticle well transfection
On the day before transfection, cells were placed in 12
well plates with each well seeded at a density of 500,000
myocytes in 1 mL of DMEM (GIBCO) media without an-
tibiotics. The transfection complexes were then prepared:
Complex 1 – One 6 μg of DNA aliquot was diluted
into 100 μL of media in an individual eppendorf vial.Complex 2- 8 μL of Lipofectamine (Invitrogen) was
diluted into 100 μL of media.
Then, complexes 1 and 2 were mixed together and
permitted to incubate at room temperature for at least
20 minutes. After 20 minutes the contents of the indi-
vidual eppendorf yields were then transferred into each
well. The plate was gently rocked then placed back in
the incubator until the first 24 hour imaging time point.
For the nanoparticle treatment wells as designated, the
500 μL filtered sterile solution was added via syringe to
each well with a 450 nm to prevent aggregates from
transferring.
Follow up fluorescent microscopy
The first set of images was taken at 24 hours post trans-
fection. Media was removed from each well prior to im-
aging and replaced prior to returning to the incubator.
The remaining set of images was taken at the 48 hour
time point.
Fluorescence images were acquired using a Nikon Eclipse
TE2000-U fluorescence microscope equipped with a Plan
Fluor × 20/0.50 objective (Nikon, Tokyo, Japan. Microscope
controlling and image processing were carried out using
Image-Pro Plus 4.5.1.27 (Media Cybernetics, Bethesda,
MD, USA).
Statistical analysis
All SEM and nanoparticle characterization data was loaded
into GraphPrism software suite for statistical testing. Single
way ANOVA was utilized to determine differences in
nanoparticle subtypes. Individual paired t-tests were
used to compare across individual groups. Bonferroni
corrections were applied for significance testing.
Results
Process capability
Over 45 nanoparticle production yields were obtained
over the development course with the optimal ranges.
The process volumes were held in a fixed ratio, featuring
water phase #1 at 1 mL, the oil phase at 3 mL, and the
outer water phase #2 at 15 mLs. Pilot runs in greater
amount adhering to this proportion scale yielded the
same quality particles. Briefly, basic guidelines for each
process phase.
Water Phase: Aspirin 1–3 mg dissolved in PVA 1% or
Prednisolone 0.02-1 mg in 10% ethanol PVA1%. It was
noted that adding additional solvents to increase drug
load in this phase resulted in failure to maintain particle
integrity and stability.
Oil Phase: The process was very flexible in terms of
changing the amount of polymer added to the system
and was stable in the range of 20 – 120 mg of either
PLGA type.
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vital stabilizer that can be readily increased. Increases
beyond 2% tended to inhibit the amount but not the
quality of generated nanoparticles. Thus, a working
range of 0.5-2% of PVA stabilizer in the outer water
phase is suitable for accommodating various drug/polymer
complexes with good stability.
Particle characterization
The results presented here summarize the characterization
for each of the 4 resultant nanoparticle types acquired from
5 consecutive runs. Polymer load was fixed at 60 mg,
aspirin 3 mg and prednisolone at 1 mg respectively.
SEM images from the various runs for each nanoparticle
type were loaded into ImageJ software for analysis. The
process consistently yields uniform, spherically shaped
formulations (Figure 2A,B). The size distribution was veryFigure 2 SEM Characterization Sizing Results. A. Narrow size distributio
B. Close up 500 nm scaling image indicates narrow size distribution in the 2
average size by drug and polymer combination. Aspirin nanoparticles of eithenarrow, of high quality and was as follows: PLGA50:50
Prednisolone [234 ± 9 nm], PLGA65:35 Prednisolone
[228 ± 7 nm], PLGA50:50 Aspirin [323 ± 13 nm] and
PLGA65:35 Aspirin [302 ± 7 nm]. ANOVA indicated
significance between the groups, specifically it was
determined that aspirin contributed to larger particles
as both PLGA50:50 and PLGA 65:35 types were signifi-
cantly larger than their matched prednisolone counter-
parts. (Figure 2C) This difference in size was most
likely attributable to both higher aspirin mass content
and charge of the first water phase in the reaction
since size was unaffected by the addition of more poly-
mer (data not shown).
Yields were very consistent and proportional to polymer
mass input in the range of 75-80% recovery upon final har-
vest. The average yields per polymer/drug type based on
60 mg input were: PLGA50:50 Prednisolone [46 ± 1 mg],n and high quality spherical shaped yield example in A at 2μm scaling.
00-350 nm range consistently for all manufactured yields. C. Nanoparticle
r 50:50 or 65:35 type had greater size (p<0.05) versus prednisolone.
Figure 4 Controlled release study results demonstrate that
aspirin particles overall release faster than prednisolone types.
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[48 ± 1 mg] and PLGA65:35 Aspirin [47 ± 2 mg]. Produc-
tion yields with increased or decreased polymer loading
revealed the same results (data not shown).
Loading Efficiency results were uniform for all 4 nano-
particle types, independent of drug or polymer and were:
PLGA50:50 Prednisolone [88.9 ± 0.01%], PLGA65:35 Pred-
nisolone [88.2 ± 0.01%], PLGA50:50 Aspirin [89.0 ± 0.01%]
and PLGA65:35 Aspirin [88.8 ± 0.01%].
Stability analysis
Positive nanoparticle visualization was realized on the
SEM 24 hours after re-constituting freeze dried product
in saline for all 4 polymer configurations. The particle
shape and size was retained.
The stability of the nanoparticles in suspension was
moderate to good in the range of −30 to −53 mV. A
score much less than −30 indicates a stability issue with
a pharmaceutical dispersion, while any score higher
than −60 indicates maximum. The potential scores by
nanoparticle type shown in Figure 3 were as follows:
PLGA50:50 Prednisolone [−47 ± 5 mV], PLGA65:35
Prednisolone [−31 ± 1 mV], PLGA50:50 Aspirin [−45 ±
0.5 mV] and PLGA65:35 Aspirin [−32 ± 0.9 mV]. Stat-
istical tests revealed that the PLGA50:50, independent
of drug load was superior compared with the 65:35
type.
Controlled release of the nanoparticle formulations
Figure 4 shows a graphical depiction of the release over
the span of 5 days. It was evident that the aspirin
released faster overall as compared with prednisolone.
This is most likely due to a combination of factors
including size, stability and charge. The PLGA50:50
Aspirin type had the fastest release profile.
Process limitations
The high quality in terms of particle shape uniformity,
yield, surface charge and release properties were criticallyFigure 3 Nanoparticle zeta potential colloidal stability testing
results indicate that the PLGA50:50 nanoparticles are more
stable in solution versus the PLGA65:35 types.limited by a number of key variables. Therefore, produc-
tion with major deviations with the water phase I input
(data not shown) resulted in lower quality profiles featur-
ing aggregation and wider size ranges. The first major crit-
ical variable was the concentration of the loading drug in
the first water phase, which was largely limited by the
inherent solubility at room temperature. In the case of as-
pirin, without solvents added, the maximum concentration
was 3 mg/mL directly at the solubility limit. Runs at the
5–10 mg/mL range resulted in aggregation and lower
quality. In the case of prednisolone, it was anticipated
that on a per gram basis at least 1 mg/mL would be re-
quired to achieve high quality in addition to a realistic
dosing paradigm for a rodent heart with target of 1
gram mass. This was achieved suitably with 10% Etha-
nol, however concentrations greater than 25% in an
attempt to load more drug distorted the process (data
not shown). The PLGA and PVA stabilizer system as
presented here is therefore open to excipient manipu-
lation provided that solubility and other attributes of
the selected drug are addressed such to prevent devia-
tions in overall quality which may or may not be de-
sired depending on the application. We anticipate this
platform would be open for further experimentation by
professional formulation scientists tailored to each
specific PLGA/drug selection for the intended direct
injection application.
In-vitro myocyte transfection
All wells were checked for viability and it was deter-
mined that none indicated any major media discolor-
ation or visual evidence of contamination. The following
5 groups all had positive detection of GFP (green) in at
least 2/3 replicate wells at both 24 and 48 hours, with a
greater degree of cells positive as expected at 48 hours.
Figure 5 depicts independent uptake of both GFP plas-
mid and nanoparticle co-signal. The absorption clusters
were confirmed in the center of myocytes. The multiple
DNA and nanoparticle infection groups yielded nano-
particle presence (red) or both (yellow) at the 24 and 48
Figure 5 In Vitro Fluorescent Imaging at 48 hours post
transfection. All 4 particle systems exhibited safe and robust uptake
in myocytes while not interfering with plasmid uptake and
subsequent GFP expression. Yellow signal indicates co-existence of
GFP and nanoparticle in: A. PLGA65:35 Aspirin B. PLGA50:50 Aspirin
C. PLGA50:50 Prednisolone D. PLGA65:35 Prednisolone.
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shown) II. GFP and PLGA65:35 Aspirin (Figure 5A)
III. GFP and PLGA50:50 Aspirin (Figure 5B) IV. GFP
and PLGA50:50 Prednisolone (Figure 5C) V. GFP and
PLGA65:35 Prednisolone (Figure 5D).Discussion
This study presents two key findings that have broad im-
plications for the advancement of cardiac gene therapies.
First a reproducible, simple to use lab scale process was
developed to generate anti-inflammatory nanoparticles
of very high quality for co-administration with gene
products in a - regulatory friendly - PLGA platform. Al-
though only two anti-inflammatory drugs were utilized
in this feasibility assessment, it is anticipated that any
other drug indicated for injection into muscle could be
introduced by modification of the first drug water phase.
Also the process offers an easy means to adjust the poly-
mer content in the oil phase for the desired degrad-
ation/release profile, along with increasing the amount
of stabilizer. Therefore this system can provide a plat-
form to guide future pre-clinical studies to investigate
reliable clinical interventions to address the role of in-
flammation on the relative performance of gene products
in muscle tissue. The potential role of inflammation
should not be overlooked, particularly in myocardial tissue
where the most common delivery scenario is in ischemicregions, which are characterized by a high degree of
inflammation and fibrosis. The second key finding in the
final test was that PLGA uptake and release of anti-
inflammatory agents in myocytes does not interfere with
the absorption and trafficking of the GFP plasmid. Muscle
tissue has a high risk of developing an adaptive immune
response to gene products. Wilson et al. described in
detail the host response after AAV delivery by route of
administration and more specifically the role of inflam-
mation [27]. A key finding with AAV mediated gene
transfer was that the host either induces tolerance or
an adaptive immune reaction through a series of com-
plex interactions [28-30]. A prime risk factor in these
interactions that was found to trigger adaptive immune
responses were inflammatory cytokines and signals ei-
ther already present in tissue or induced at the time of
delivery [31]. It has been postulated that with attenu-
ation of innate inflammatory response signals, the im-
mune system has a much lower risk for mounting
maladaptive T cell responses. Using the example of
AAV, once vector capsid antigens are cleared from the
system, typically 12–16 weeks after delivery, there is a
good chance for therapeutic tolerance. The risk is that
an adaptive immune response will destroy those cells
expressing the transgene of interest well before these
antigens are cleared. Use of anti-inflammatory agents
to mitigate the innate response to injury is likely to re-
sult in enhanced long term gene expression. Intraven-
ous delivery approaches are associated with a lower
level of induced inflammation but are also very ineffi-
cient. In contrast, the IM route in the heart remains at-
tractive because greater cardiac specificity can be achieved,
especially for angiogenesis or regenerative therapies that
require a more local delivery profile. Yet IM delivery is
associated with a more robust innate immune response
due to associated tissue injury.
Direct injection into healthy or ischemic myocardial
regions introduces the gene product into a highly in-
flammatory region, which likely explains the poor car-
diac gene therapy results with IM interventions. Early
studies by Snyder et al. [32] reported that very little suc-
cessful transfer occurs in damaged muscle in the inflam-
matory environment. Numerous examples have validated
these observations in gene therapy trials. In hemophilia
trials for example it was found that IM injection into
skeletal muscle resulted in transient therapeutic gene
expression and an adaptive CD4+ immune response
[33,34]. However, delivery of the same product infused
into the liver has resulted in better outcomes and lim-
ited reactions. Muscular dystrophy trials have encoun-
tered similar difficulties and have attempted to utilize
immunosuppressant drugs and other agents to limit
responses after multiple IM injections compromising
patient safety [35].
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In this proof of concept study, GFP plasmid was utilized
to simulate a therapeutic construct understanding that
naked DNA is likely to be at the lower end in terms of
transduction efficiency. For more practical gene therapy
applications, it is anticipated that viral vectors encoding
the gene of interest could readily be combined with par-
ticles containing potent anti-inflammatory drugs. The
hypothesis offered is that with the right formulation, the
anti-inflammatory agent would be released at the suffi-
cient level over the critical post-delivery inflammatory
period to provide an optimal viral vector trafficking
microenvironment. There would be a predicted increase
in transduction efficiency, minimize the innate and adap-
tive immune response to the vector and/or transgene and
promote long term gene expression in the target tissues.
This strategy of course would not be without its own limi-
tations and would require much more experimentation
to determine the best matched drug and release profile
for co-administration into the heart. More complex
approaches in managing the host response following
therapy have been applied, however it may turn out
that simply addressing the innate immune response at
the time of delivery may be a meritorious approach to
advance successful clinical translation.Competing interests
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